1. Generics Bulletin
  2. >>Leadership

Stada Recruits Ex-Sandoz Exec To Help Steer Biosimilars

Christine Berndt Previously Headed Biosimilar Development Programs At Sandoz

 
• By Dave Wallace

Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.

Wooden blocks leader selected chosen people put forward
Christine Berndt will be head of global development for specialty/biosimilar drugs at Stada • Source: Paradee Kietsirikul / Alamy Stock Photo

Christine Berndt, a former Sandoz executive who was a global program head for four biosimilar programs at the company, is to join Stada from June as head of global development for the German firm’s specialty and biosimilar division, with responsibility for “the development strategy and execution of Stada’s growing specialties and biosimilars portfolio.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.